Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis.

ABSTRACT:

Objective

This meta-analysis synthesizes evidence from all available randomized trials and observational cohort studies evaluating the efficacy and safety of ocrelizumab compared to placebo or active comparator therapies.

Background

Ocrelizumab (OCR), a monoclonal antibody targeting CD20-positive B-cells, is a high-efficacy therapy for multiple sclerosis (MS). While pivotal trials demonstrate its efficacy in reducing relapses, its impact on disability progression and its safety profile in broader, real-world populations require further synthesis.

Methods

This systematic review and meta-analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420251012243). We searched PubMed, Embase, and Cochrane Central until August, 2025, for randomized controlled tria

SUBMITTER: Nawaz A 

PROVIDER: S-EPMC12754981 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature